# Xeltis

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xeltis-b-v

- Industry: Medical Devices & Equipment
- Headquarters: Eindhoven, Netherlands
- Website: www.xeltis.com
- Total disclosed funding: $124M
- Latest round: Series D (Feb 21, 2023)
- Investors on record: 7

## About

Based in the Netherlands, Xeltis AG specializes in innovative vascular implants aimed at improving outcomes for patients with cardiovascular conditions through bioresorbable solutions, designed to facilitate natural healing and tissue regeneration. 

Xeltis AG, founded in 2006 and co-founded by Laurent Grandidier and Martijn Cox, focuses on developing bioresorbable vascular grafts and patches for cardiovascular applications. The company is headquartered in Eindhoven, Netherlands. Eliane Schutte serves as the CEO. In July 2026, Xeltis B.V. raised EUR 20.5 million in venture funding led by Horizon 3 Healthcare, with participation from European Innovation Council, Invest-NL, Vi Partners, EQT Life Sciences, and DaVita Venture Group. 

Xeltis specializes in transformative vascular implants designed to address a range of cardiovascular conditions. Their core product offerings revolve around bioresorbable vascular grafts and patches that facilitate the natural healing process by promoting tissue regeneration. These innovative implants are engineered to integrate with the body’s own tissues, offering a long-term solution for patients suffering from vascular diseases. The primary end users of Xeltis’ products include hospitals, cardiovascular surgeons, and healthcare providers across Europe and North America, where they aim to improve surgical outcomes and enhance the quality of life for patients. By aligning their products with the needs of healthcare professionals, Xeltis addresses critical use cases such as congenital heart defects and arterial blockages, contributing to advancements in the field of cardiovascular therapy.

Xeltis generates revenue through direct sales of its innovative vascular implants to healthcare institutions and practitioners. The transaction structure typically involves B2B sales, where hospitals and surgical centers purchase the implants for use in various cardiovascular procedures. Revenue is driven by the demand for Xeltis' flagship products, which are marketed based on their unique capacity to promote natural healing and tissue integration. Pricing plans for the implants are structured to reflect their advanced technology and clinical benefits, allowing healthcare providers to access these solutions for their patients. The company maintains a strategic focus on fostering relationships with healthcare professionals to facilitate the adoption of their products, which plays a critical role in their revenue generation strategy. Xeltis AG is actively working on new products aimed at enhancing its vascular implant offerings. 

The company plans to use the July 2026 funding to complete the aXess™ trial, prepare for FDA submission, expand manufacturing, and advance clinical programs

## Funding rounds

- Series D, Feb 21, 2023, $34M — EQT Life Sciences, DaVita Venture Group, Invest-NL, China Grand Pharmaceutical and Healthcare Holdings Limited
- Series D, Sep 5, 2019, $12M — EQT Life Sciences, Ysios Capital Partners, Kurma Partners, Vi Partners
- Series C, Nov 15, 2017, $45M — EQT Life Sciences, Ysios Capital Partners, Kurma Partners, Vi Partners
- Series B, Dec 2, 2014, $34M — EQT Life Sciences, Kurma Partners, Vi Partners

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B, Series C, Series D
- Kurma Partners (https://capitalatlas.ai/funds/kurma-partners) — Series B, Series C, Series D
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series B, Series C, Series D
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series C, Series D
- DaVita Venture Group (https://capitalatlas.ai/funds/davita-venture-group) — Series D
- Invest-NL — Series D
- China Grand Pharmaceutical and Healthcare Holdings Limited — Series D